Anticardiolipin antibodies in unexplained pregnancy loss by Melita Keren Glady, S B
ANTICARDIOLIPIN ANTIBODIES IN 
UNEXPLAINED PREGNANCY LOSS
Dissertation submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY
In partial fulfilment of the regulations
for the award of the degree of
M.D. BRANCH-II
OBSTETRICS AND GYNAECOLOGY
GOVT. R.S.R.M. LYING-IN HOSPITAL AND
GOVT. STANLEY MEDICAL COLLEGE & HOSPITAL
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY
CHENNAI, INDIA.
MARCH 2009 
                          CERTIFICATE
               This  is  to  certify  that  this  dissertation  titled 
“ANTICARDIOLIPIN  ANTIBODIES  IN  UNEXPLAINED 
PREGNANCY  LOSS’’ is  a  bonafide  record  of  work  done  by 
Dr.S.B. Melita Keren Glady  during the  period of her Post graduate study 
from  May  2006  to  March  2009  under  guidance  and  supervision  in  the 
Department  of  Obstetrics  and  Gynaecology,  Raja  Sir  Savalai  Ramasamy 
Mudaliar  Hospital,  Stanley Medical  College Hospital,  Chennai-600013 in 
partial  fulfilment of the requirement for  M.D. Branch-II Obstetrics and 
Gynaecology Examination of the Tamilnadu Dr. M.G.R. Medical University 
to be held in March 2009.
Dr.J. MOHANASUNDARAM, M.D., D.N.B., Ph.D.,
DEAN
Stanley Medical College,
Chennai -600 001
Dr.M.MOHANAMBAL, M.D. D.G.O., HOD, 
Superintendent, 
Department of Obstetrics & Gynaecology,
Government RSRM Hospital,
Stanley Medical College,
Chennai -600 013
ACKNOWLEDGEMENT
I am grateful to  Dr. J.MOHANASUNDARAM, M.D., Ph.D.,DNB, 
Dean  of  Stanley  Medical  College  for  granting  me  permission  to  do  this 
dissertation.
I  owe  my  deep  sense  of  gratitude  to  PROF.  DR.M. 
MOHANAMBAL, M.D., D.G.O., Superintendent, Govt. R.S.R.M Lying-In 
Hospital  who  not  only  permitted  me  to  do  this  study  but  also  her 
encouragement and guidance helped me to complete the task  successfully. 
I extend my heartfelt thanks to PROF. DR. AMRITA PRISCILLA 
NALINI, M.D., D.G.O., Deputy Superintendent, Govt. R.S.R.M Lying-In 
Hospital  for  her  able  guidance  and  constant  support  which  helped  me 
throughout the study.
I am thankful to PROF. DR. P.SASIREKHA M.D., D.G.O., PROF. 
DR. C.R.ANURADHA M.D., D.G.O., & PROF. DR. C.K.RAJINI M.D., 
D.G.O., for their valuable opinions and guidance.
I would like to thank PROF.DR. N.HEPHZIBAH KIRUBAMANI 
M.D.,  D.G.O.,  PhD. Resident  Medical  Officer,  Govt.  R.S.R.M Lying-In 
Hospital for her immense support and encouragement.
My  Sincere  thanks  to  PROF.  DR.  THENMOZHI  VALLI  M.D., 
HOD,  Dept.  of  Microbiology,  Stanley  Medical  College  for  her  support 
during the study. 
I  also  thank  all  my  Assistant  Professors  for  their  Valuable 
suggestions. 
Finally my heart felt thanks go to the patients without whom this work 
wouldn’t have been possible.  
CONTENTS
SL.NO             TITLE         PAGENO.
1. INTRODUCTION      1
2. AIM OF STUDY                                               6
3. REVIEW OF LITERATURE                               7 
4. MATERIALS AND METHODS           38
5. OBSERVATION                                            44
6. DISCUSSION 52
7. SUMMARY  60
8. CONCLUSION 62
9. BIBLIOGRAPHY
10. PROFORMA
11. MASTER CHART
                                    INTRODUC
TION
INTRODUCTION
Man has amazing interest in research and his thirst for knowledge has 
begun right from the era of Stone Age. But what perhaps escapes his mind is 
that the human body is the most fascinating thing available and demands 
more exploration than anything else.
The science of immunology is one such breath taking field and the 
ability of human being to discriminate between self and non-self antigens is 
phenomenal. The recognition and the response to foreign antigens, an ability 
perhaps most  highly developed in mammalian species  is one of the most 
intensively studied topics in science and medicine today. 
Pregnancy  is  an  unique  immunological  stage  where  a  natural 
homeostasis exists between antigenically different tissues. 
            One of the Medawars initial hypothesis, on the maintenance of the 
foetal allograft was that pregnancy was associated with suppression of the 
maternal immune response thereby allowing foetal survival. The pregnant 
host  however  must  also  maintain  immunocompetence  against  both 
pathogenic  and  neoplastic  invasion  during  the  gestation  to  ensure  host 
survival. 
Autoimmunity  is  one  deviation  from  this  normal  pattern,  where 
antibodies are directed against one’s own antigens. One of the fundamental 
questions  in  the  study  of  any  autoimmune  disease  concerns  the  role  of 
autoantibodies in the pathogenesis of the disorder. In certain autoimmune 
conditions like Grave’s disease and Myasthenia gravis the evidence that they 
are directly involved in the pathogenesis is strong.
Much recently interest has been focussed over the Antiphospholipid 
Antibody syndrome. Antiphospholipids were first linked to pregnancy loss 
more  than  30  years  ago  and  the  condition  known  as  antiphospholipid 
syndrome is perhaps the most  convincing immune disturbance other than 
antierythrocyte and antiplatelet alloimmune disorders.  Specific criteria for 
antiphospholipid  syndrome  have  been  delineated  and  the  anticardiolipin 
assay  has  been  standardized  and authorities  have  agreed on a  laboratory 
criteria to define lupus anticoagulant.
        
            In the last 25 years, numerous investigators have described the 
association  between  antibodies  that  bind  phospholipid  molecules  and 
repetitive pregnancy losses.  Antiphospholipid antibodies account for 3% to 
5% of patients with repetitive pregnancy losses. The frequency of fetal death 
and recurrent abortion in untreated patients with antiphospholipid antibodies 
is greater than 90%.13
          The prevalence of antiphospholipid antibodies in general population is 
around 2-4%.  Of patients  with the  antiphospholipid antibody syndrome, 
over  50% of them have the primary antiphospholipid antibody syndrome. 
In persons with systemic lupus erythematosus, around 30% will develop the 
antiphospholipid  antibody  syndrome.   The  two  best   characterised 
antiphospholipid  antibodies,  lupus  anticoagulant  and  anticardiolipin 
antibodies have been widely recognised as risk factors for  pregnancy related 
complications  including  recurrent  pregnancy  loss,  intrauterine  growth 
retardation, pre-eclampsia,  antepartum haemorrhage and the failure of in-
vitro fertilisation and embryo transfer, thus emerging as a clinical entity of 
“reproductive autoimmune failure syndrome”.2  In general,  anticardiolipin 
antibodies are more common than the lupus anticoagulant in patients with 
the antiphospholipid antibody syndrome.6
Nonetheless considerable confusion exists regarding antiphospholipid 
syndrome and related reproductive problems. The state of affairs primarily 
derives from two problems; the first  is the premature introduction of non 
standardized  antiphospholipid  assays  into  clinical  use,  without  proper 
standardization, as a result of which less well versed clinicians sometimes 
make  the  diagnosis  of  antiphospholipid  syndrome  in  women  who  are 
negative for lupus anti coagulant and anticardiolipin antibody.
                A second major problem is that of unwarranted discrepancies in 
the clinical and laboratory features of patients considered to have a diagnosis 
of antiphospholipid syndrome. This problem is most  apparent in the case 
selection for screening and management protocol.
Our entire work revolves around,
a. Whether these anticardiolipin antibodies are a  direct cause of  
pregnancy  loss (or) merely an epiphenomenon.
b. Criteria for screening a woman for anticardiolipin antibodies
c. The kind of obstetric outcome and pregnancy loss that is common 
in patients who are anticardiolipin antibody positive.
Anticardiolipin antibody is found to have a higher predictive power than 
lupus anticoagulant for foetal loss (Pattison et al).  According to Lynch et al 
and various other researchers an elevated IgG anticardiolipin antibody was 
the only antiphospholipid antibody to be significantly associated with the 
foetal demise. So IgG anticardiolipin antibody has been exclusively studied 
in this work.
                                  AIM OF 
STUDY
AIM OF STUDY
To evaluate  the presence  of  Anticardiolipin antibodies  in  women 
with unexplained pregnancy loss.
To  assess  the  type  of  common  obstetric  outcome  in 
Anticardiolipin Antibody positive women.
REVIEW OF LITERATURE
REVIEW OF LITERATURE
The incidence of habitual abortion is in the range of 0.4-0.8% and in 
approximately half of these cases a specific etiologic factor can be found. 
3-5%  of  habitual  abortion  cases  are  thought  to  be  due  to  autoimmune 
abnormalities.  Anticardiolipin antibodies and lupus anticoagulant factor are 
the two antiphospholipid antibodies which have a role in this situation4.
          
Cardiolipins are negatively charged phospholipids which are obtained 
from  beef  heart  with  alcoholic  extraction.   This  is  the  basis  of  the 
flocculation test, VDRL, which has been used in the diagnosis of syphilis 
until  recent  years.   The tissue damage in syphilis  results in formation of 
some  auto  antibodies  which  react  with  cardiolipin  and  some  other 
phospholipids.   Today  Lupus  Anticoagulant  Factor  and  AntiCardiolipin 
Antibody are found in many disorders characterized by  arterial and venous 
thrombosis,  habitual  abortion,  intrauterine  growth  retardation  and 
intrauterine fetal death4.  
               Most sensitive tests for the detection of anticardiolipin antibodies 
are the solid phase RIA and ELISA techniques in which microplates covered 
with  cardiolipin  antigens  react  with  anticardiolipin  antibodies.   Lupus 
Anticoagulant  Factor  is  detected  indirectly  by  prolongation  of  activated 
partial thromboplastin time test (APTT).  It can also be detected by several 
other  coagulation  tests  (Kaolin  clotting  time,  Tissue  thromboplastin 
inhibition test).
HISTORY
              Historically, antiphospholipid antibodies were first noted in patients 
who had positive tests for syphilis without signs of infection.  Subsequently, 
a  clotting  disorder  was  associated  with  two patients  with systemic  lupus 
erythematosus in 1952.  In 1957, a link between recurrent pregnancy loss 
and what is now called the lupus anticoagulant was established by Laurell 
and Nillson6. They described a patient with five prior intrauterine deaths who 
had a biologically false-positive syphilis test and an anticoagulant antibody. 
Later  it  was  found  that  the  circulating  anticoagulant  and  the  molecule 
responsible  for  the  false  positive  serology  were  antiphospholipid 
antibodies13.  Ultimately,  the  lupus  anticoagulant  was  further  described  in 
1963 and in 1972 the term lupus anticoagulant  was given.   In 1983,  Dr. 
Graham  Hughes  described  the  association  between  antiphospholipid 
antibodies and arterial as well as venous thrombosis.6
             Feinstein  and  Rapaport  (1972)  introduced  the  term  lupus 
anticoagulant (LAC) in a review of acquired inhibitors of coagulation.  This 
was based on early recognition that certain patients with lupus had some 
coagulation  tests  that  were  prolonged  and  thus  suggested  anticoagulant 
activity.  Paradoxically, the so called anticoagulant is powerfully thrombotic 
in vivo, although the LAC prolongs all phospholipid dependent coagulation 
tests,  including the prothrombin time, partial thromboplastin time, Russell 
viper venom time,  Each of these tests requires a phospholipid surface to 
which other clotting factors attach and combine.  Thus detection of LAC is 
based  indirectly  on  the  prolongation  of  in  vitro  tests  by  this  circulating 
antiphospholipid  antibody.   ACA is  detected  serologically  using  enzyme 
linked  immunosorbent  assay  (ELISA).   Most  often  IgM  anticardiolipin 
antibodies that are found alone are stimulated by infections or drugs and are 
innocuous. (Silver et al)14.
            Antiphospholipid Syndrome may be either primary if other features 
of  connective  tissue  disease  are  absent  or  secondary  to  established 
connective  tissue  diseases  such  as  systematic  lupus  erythematosus.  It  is 
argued that primary APS is misnomer, i.e., primary APS is only a Prodromal 
State before the patient develops other features of Autoimmune Disease – 
Secondary  APS.  More  recent  studies  suggest  that  antibodies  that  really 
matter are beta2 glyco protein, the cofactor by which anticardiolipin binds to 
phospholipids. Patients who have cardiolipin antibodies in high titre usually 
have high levels of lupus anticoagulant.(Michael de Swiet et al). 11
Cardiolipin antibodies may belong to both IgG and IgM subtypes. The 
IgG antibodies seem to be a better predictor of fetal outcome, although the 
presence of IgM antibodies is not without risk to the fetus. 11   
PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODY
Studies have reported that the prevalence of anticardiolipin antibody 
in  women  with  three  or  more  miscarriages  is  between  11%  and  42% 
(BIRDSALL  et  al.,  BARBUE  et  al.,  CREAGH  et  al.,  PARKE  et  al., 
UNANDER et al.,) in contrast to prevalence of 2% in women with a low risk 
obstetric history.
Category No of Subjects
Lupus 
anticoagulant 
Anticardiolipi
n Antibody Reference
Low Risk 
Population 
933 1.00% 1.20%
PATTISON 
et al.,31 
Recurrent 
Miscarriage
500 9.10% 5.50% RAI et al.,32 
In RAI et al.’s study IgG anticardiolipin antibody was found in 3.3% 
and prevalence of the IgM anticardiolipin was 2.2 %
EROGLU et  al.,  in  their  research  suggested  that  the prevalence  of 
anticardiolipin antibody is very low in first trimester losses and is not very 
significant. 33 MACLEAN  and  colleagues  in  their  study  proved  that 
anticardiolipin antibody had a prevalence of 8.2% in first trimester losses. 34 
Bocconi  from  catholic  university,  Italy  suggested  that  anticardiolipin 
antibody is  found in  20.5% in those with unexplained pregnancy loss. 35 
Nevertheless,  APL antibodies are found in upto 5% of apparently healthy 
controls and upto 35% of patients with SLE. 
PATHOPHYSIOLOGY  OF  ANTIPHOSPHOLIPID 
ANTIBODIES IN PREGNANCY14
According to Charmley 1999, platelets may be damaged directly by 
antiphospholipid antibodies or indirectly by binding Beta 2 Glycoprotein I 
which causes platelets to be susceptible for aggregation. Rand et al 1997, 
proposed  that  phospholipids  containing  endothelial  cell  or 
syncytiotrophoblast    membranes  may  be  damaged  directly  by  the 
antiphospholipid antibody or indirectly by antibody binding to either Beta 2 
GlycoProtien1  or  Annexin  V.  This  prevents  the  cell  membrane  from 
protecting  the  syncytiotrophoblast  and  endothelial  cells  and  results  in 
exposure of basement membrane. 
Pierro and Co-workers 1999 reported that antiphospholipid antibodies 
decrease  the  decidual  production  of  the  vasodilating  prostaglandin  E2. 
Decreased  Protein  C  or  S  activity  as  well  as  increased  prothrombin 
activation has reported by Ogunyemi et al 2002. Recent studies suggest that 
uncontrolled  placental  complement  activation  by  antiphospholipid 
antibodies may play a role in fetal loss and growth restriction. 
     
MECHANISM OF ACTION
The  Placenta  is  severely  infarcted  and  the  foetus  is  often  growth 
restricted.  Even in  the  pregnancy  of  those  foetuses  that  survived,  severe 
preeclampsia is very common. Current theories centre round the damage to 
placental  vascular  endothelium caused  by  cardiolipin  antibodies,  platelet 
deposition  and  imbalance  to  thromboxane/prostacyclin  production  tilted 
towards  too  much  thromboxane  and  too  little  prostacyclin  all  leading  to 
inadequate maternal placental perfusion. 11
Inhibition of protein C and tissue plasminogen activator has also been 
postulated  as   mechanisms  whereby  lupus  anticoagulant  may  cause 
thrombosis. 
MECHANISMS OF REDUCTION OF ANNEXIN V LEVELS 
AND ACCELERATION OF COAGULATION ASSOCIATED 
WITH ANTIPHOSPHOLIPID ANTIBODIES 14
 A relative lack of Annexin V a naturally occurring anti coagulant on 
the intervillous surfaces of the placenta may be a contributing factor.  
       Anionic phospholipids on the surface of cell membrane bilayer serve as 
potent  co  factors  for  assembly  of  three  coagulation   complexes—tissue 
factor-VIIa  complex,  IXa-VIIIa  complex  and  Xa-Va  complex.  When 
antiphospholipid antibodies are absent, annexin V forms clusters that bind to 
the surfaces of anionic phospholipids and inhibit coagulation.
             In antiphospholipid antibody syndrome, directly or through an 
interaction with protein phospholipid co-factors, they disrupt the ability of 
annexin  V  to  cluster  on  the  phospholipid  surface.  This  reduces  binding 
affinity  of  annexin  V,  which  permits  more  anionic  phospholipids  to  be 
available to form complexes with coagulation proteins.  Coagulation is thus 
accelerated and thrombosis promoted.
DIAGNOSTIC CRITERIA OF 
ANTIPHOSPHOLIPID SYNDROME12
The  first  classification  criteria  for  the  diagnosis  of  APS  was 
formulated in conference workshop in October 1998 at Sapparo, Japan and 
referred to as Sapparo Criteria.
They have been recently revised, the major change being essentially 
the addition of anti beta 2 glyco protein 1 antibody as one of the laboratory 
criteria  and  documentation  of  persistence  of  the  antibodies  for  a  longer 
duration by repeating the test at 12 Weeks instead of 6 Weeks.
REVISED CLASSIFICATION CRITERIA FOR 
ANTIPHOSPHOLIPID SYNDROME
Clinical Criteria
1. Vascular thrombosis: one or more episode of arterial, venous or 
small vessel thrombosis in any organ.  
2. Pregnancy morbidity: 
a. One or more unexplained death of a morphologically normal 
foetus ≥ 10 Weeks of Gestation.
b. One or  more premature birth before 34 weeks because of 
eclampsia, preeclampsia or placental insufficiency.   
c. Three  or  more  unexplained  spontaneous  consecutive 
abortion  before  10  weeks  of  gestation  with  maternal 
anatomic,  hormonal  and  paternal  karyotype  abnormalities 
excluded.
Laboratory Criteria
1. Lupus  anticoagulant  present  in  serum/plasma  on  two  or  more 
occasion atleast 12 weeks apart detected.
2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or 
plasma present in medium or high titre on two or more occasions 
atleast 12 weeks apart.  
3. Anti beta 2 Glyco protein 1 antibody of IgG and/or IgM isotype in 
serum or plasma present in two or more occasions atleast 12 weeks 
apart. 
CLINICAL FEATURES OF THE 
ANTIPHOSPHOLIPID SYNDROME11
Thrombosis
Venous
Recurrent  deep vein thrombosis  (also intravascular  coagulation and 
retinal vein thrombosis)
Arterial
Cerebrovascular accidents
Peripheral arterial gangrene
Coronary thrombosis
Retinal artery thrombosis
Other
Pulmonary hypertension
 avascular necrosis
Abortion
Recurrent IUD, placental thrombosis and infarction.
Thrombocytopenia
Intermittent, often acute
Other occasional features
Coombs positivity
Livido reticularis
Migraine
Chorea
Epilepsy
Chronic leg ulcers
Endocardial disease
Progressive  dementia  due  to  repeated  cerebrovascular 
thrombosis
WHAT PROBLEMS DO APLA CAUSE?8
PREGNANCY COMPLICATIONS:
             APLA are present in approximately 10% to 20% of women 
with  recurrent  miscarriage.   Women  with  APLA  have  a  higher  risk  of 
pregnancy loss at  or after 10 weeks of pregnancy.  This is in contrast to 
pregnancy  loss  in  the  general  population,  which  occurs  more  commonly 
before 10 weeks of pregnancy.  Additionally APLA is associated with other 
pregnancy complications, including eclampsia, preeclampsia, and placental 
insufficiency.
VENOUS CLOTS:
                      One of the complications of APLA are clots in the veins, most 
commonly either a Deep Vein Thrombosis in the leg or a pulmonary emboli 
in the lung.  Less common locations for venous clots include the superficial 
veins (superficial thrombophlebitis), the eye, the abdomen, in or around the 
brain, and in or around the liver.
ARTERIAL CLOTS:
                          APLA may also cause clots in the arteries such as stroke, 
heart attack, and clots in the arteries of the arm, leg, eye, kidney or abdomen. 
Suspicion  for  the presence  of  APLA in a  person with  an  arterial  clot  is 
higher if the person has no obvious risk factor for arterial disease (such as 
diabetes,  high  blood  pressure,  high  cholesterol),  does  not  smoke  or  is 
relatively young.
OTHER CLINICAL PRESENTATIONS
                              Many studies show that APLA can be associated with a  
variety  of  other  clinical  findings,  including  low platelets,  anaemia,  heart 
valve disease, skin rashes, mini-strokes, joint pain, joint inflammation, dry 
eyes and dry mouth.
CATASTROPHIC APLA SYNDROME8
          Most patients with APLA who develop clots will develop them as 
individual events and possibly have recurrent clots at a later time.  However, 
a very small group of people with APLA develop multiple clots in different 
organ systems throughout the body within a matter of days.  This is called 
catastrophic  APLA syndrome.  Clots  may  occur  at  the  same  time  in  the 
kidney,  brain,  heart,  extremities,  lungs and /or other organs, with resultant 
multi  organ failure and high risk of mortality.   The treatments  are blood 
thinners, steroids, plasma exchange, and possibly suppression of the immune 
system.
THE ASYMPTOMATIC INDIVIDUAL WITH APLA8
             Some people with APLA will  never develop blood clots or 
experience pregnancy loss.  Few datas are available on the risk of blood clot 
or pregnancy loss in an asymptomatic individual with APLA.  One percent 
of  people  may develop a blood clot  every year.   There are  presently  no 
recommendations  that  support  the  routine  use  of  blood  thinners  in 
asymptomatic  people.   However,  one  aspirin  per  day  appears  to  be 
beneficial.
Asymptomatic individuals should take the following precautions: 
a) Inform health care providers that they have APLA
b) Consider use of short term blood thinners to prevent a clot during 
       situations those increase the risk of developing a clot (such as 
       surgery or immobilization)
c) Know the symptoms of DVT ( swelling and pain throughout the leg, l
warmth, and discoloration) and pulmonary embolism (sudden chest pain 
and   shortness of breath)
d) Seek medical care immediately if symptoms of Deep vein thrombosis 
      or Pulmonary   edema develop  and   inform the physicians  the      
       presence of APLA in their blood.
e) Modify their  risk factors for arterial and venous blood clots, including     
avoiding  hormone  therapy,  not  smoking,  normalizing  weight,  and 
controlling blood pressure, cholesterol and blood sugar. 
RISKS OF ANTIPHOSPHOLIPID SYNDROME 
AND PREGNANCY
THROMBOTIC COMPLICATIONS OF 
ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY4
Numerous  retrospective  studies  confirm  a  link  between 
Antiphospholipid  syndrome  and  venous  or  arterial  thrombosis. 
Approximately  70%  of  thrombotic  events  occur  in  the  venous  system, 
although arterial thrombosis and cerebrovascular accidents are also common. 
Transient  CNS  manifestations  of  ischemia  are  also  common  in  APLA 
patients. Antiphospholipid antibodies are present in approximately 
2%  of  individuals  with  unexplained  thrombosis  and  are  the  only 
identifiable  pre  disposing  factor  in  4%  to  28%  of  cases  of  stroke  in 
otherwise  healthy  patients  younger  than  age  50.  The  life  time  risk  of 
thrombo embolism in women with APLA is unknown. However over half 
occur in relation to pregnancy or in use of combination oral contraceptives. 
Central  Nervous  system  involvement  is  one  of  the  most 
prominent  clinical  manifestations  and  includes  arterial  and  venous 
thrombotic  events,  psychiatric  features,  and  other  non  thrombotic 
neurological syndromes (Sanna et al 2003). Interestingly, APLA may mimic 
the presentation of multiple sclerosis (Ruiz-Irastona et al, 2001). 14
OBSTETRIC COMPLICATIONS OF 
ANTIPHOSHPHOLIPID SYNDROME IN PREGNANCY4
1. GESTATIONAL HYPERTENSION/ PREECLAMPSIA
The  median  rate  of  gestational  hypertension/  preeclampsia  in 
pregnancies  complicated  by  APLA  is  32%,  with  a  range  upto  50%. 
Preeclampsia may develop as early as 15 to 17 weeks gestation. The rate of 
gestational  hyper  tension/  preeclampsia  does  not  appear  to  be  markedly 
diminished by treatment with either glucocorticoids and low dose aspirin or 
heparin and low dose aspirin. Two groups of investigators have reported that 
women with early onset, severe preeclampsia are more likely to test positive 
for  aPL antibodies  compare  to  healthy controls.  Based  on these findings 
testing for aPL antibodies should only be considered in early onset, severe 
preeclampsia.
2. UTERO PLACENTAL INSUFFICIENCY AND PRETERM BIRTH 
Several  investigators  have  found  relatively  high  rates  of  IUGR  in 
association  with  aPL  antibodies.  Even  with  currently  used  treatment 
protocols, the rate of IUGR approaches 30%. Pregnancies complicated by 
APS are also most likely to exhibit non reassuring fetal heart rate patterns 
during antenatal tests of fetal well being and intra partum monitoring. Not 
surprisingly, the rate of pre term birth in these series ranges from 32% to 
65%.
3. PREGNANCY LOSS4
Atleast  40%  of  pregnancy  loss  reported  by  women  with  lupus 
anticoagulant  or  medium  to  high  positive  IgG  anticardiolipin  antibodies 
occur in the fetal period. According to recent prospective studies, the rates of 
obstetric complications were relatively low, with fetal death, preeclampsia, 
and pre term birth occurring in 4.5%, 10.5% and 10.5% respectively. Only 1 
of 300 women suffered a thrombotic event, and no neonatal deaths due to 
complications of prematurity were reported. 
Fetal  demise  can  occur  at  any  stage  of  pregnancy  and there  is  an 
association  with  severe  preeclampsia,  intrauterine  growth  retardation  and 
placental abruption. The reported fetal loss rate is of the order of 80% for 
those women with raised titres of anti cardiolipin antibodies. 5
According to Oshiro et al 1996 and Roque et al 2001 fetal deaths are 
more common than first trimester miscarriages. Polzin et al (1991) identified 
antiphospholipid antibodies in a fourth of 37 women with growth restricted 
foetuses. Branch et al (1989) found a 16% incidence of 
antiphospholipid antibodies in 43 women with severe preeclampsia 
before 34 weeks. Similarly Moodley et al (1995) found antibodies in 11% of 
34 women with severe preeclampsia before 30 weeks. 14
4.  POSTPARTUM  AND  CATASTROPHIC  ANTIPHOSPHOLIPID 
SYNDROME4
Catastrophic APLA is rare but devastating syndrome characterised by 
multiple  simultaneous  vascular  occlusions  throughout  the  body,  often 
resulting  in  death.  The  diagnosis  should  be  suspected  if  atleast  3  organ 
systems are affected and confirmed if there is histopathologic evidence of 
acute  thrombotic  microangiopathy  affecting  small  vessels.  Renal 
involvement occurs in 78% of patients. 
Most  have  hypertension;  25%  eventually  require  dialysis.  Other 
common  manifestations  described  by  Asherson  include  adult  respiratory 
distress  syndrome  (66%)  cerebral  microthrombi  and  microinfarct(56%), 
myocardial  microthrombi(50%),  dermatological  abnormalities  (50%)  and 
disseminated  intravascular  coagulation  (25%).  Death  from  multi  organ 
failure occurs in 50% of patients. Although no treatment has shown in to be 
superior  to another,  a  combination of  anticoagulants (usually  heparin)and 
steroids  plus either  plasmapheresis  or  IVIG has  been successful  in  some 
patients.  Streptokinase  and  urokinase  have  also  been  used  to  treat  acute 
vascular thrombosis.    
Indications to test for Antiphospholipid antibodies14
1. Recurrent pregnancy loss
2. Unexplained second or third trimester loss
3. Early onset severe Preeclampsia 
4. Venous or Arterial thrombosis
5. Unexplained fetal growth restriction
6. Autoimmune or Connective tissue diseases
7. False positive serological test for syphilis
8. Prolonged coagulation studies 
9. Positive auto antibody test
LABORATORY TESTS LIKELY TO BE ABNORMAL IN PATIENTS 
WITH ANTIPHOSPHOLIPID SYNDROME51 
 Partial thromboplastin time (PTT).
 PTT  remains  prolonged  when  the  patient’s  plasma  is  mixed  with 
normal plasma. Positive “mixing study”
 Kaolin clotting time (KCT)
 Russell viper venom time (RVVT)
 Low platelet count
 Anticardiolipin antibody IgG and IgM 
 Beta 2 glycoprotein I dependent Anticardiolipin antibody
 Serologic tests for syphilis
 Antinuclear antibody
WHO SHOULD BE TESTED FOR APLA AND HOW OFTEN? 8
People who have had one of the clinical events listed in the diagnostic 
criteria and who do not have other identifiable reasons for blood clots or 
pregnancy losses should be tested for  APLA. If they have found to have 
APLA, the test should be rechecked atleast 12 weeks later. If the second test 
is again positive, they can be categorised as having APLA syndrome. If a 
person has one positive APLA test followed by a negative APLA test 12 
weeks later, the test  should be repeated again in  6 months.  If the test  is 
negative twice, the person does not have APLA syndrome.8
HOW DO YOU TEST FOR APLA?
              There are two ways to test the blood for the presence of APLA. One 
test is a direct measurement of the amount of antibody present. Because the 
immune system can make APLA against a variety of different phospholipids 
or  proteins  bound  to  phospholipids  (for  example,  cardiolipin,  beta2 
glycoprotein I), a variety of tests can be performed.  Furthermore, because 
our immune system can make three different forms of antibodies, referred to 
as immunoglobulin (IgG, IgM, IgA), three different tests can be performed 
for each phospholipids.  These tests are poorly standardized, which cause 
problems  when  interpreting  the  results  or  comparing  results  from  one 
laboratory to those of another.8
The other way to look for the presence of APLA is by measuring the 
effect that the antibodies have on the clotting system in the test tube (lupus 
anticoagulant test).  A variety of clotting tests are used for this purpose, most 
commonly  the  Rusell  viper  venom  (RVVT)-based  test  and  the  Lupus 
anticoagulant partial thromboplastin time (LA-PTT) based test.8 
Although  anticardiolipin  antibodies  are  more  common  than  lupus 
anticoagulants, the presence of a lupus anticoagulant puts a person at high 
risk of  having a clot  than does the presence of anticardiolipin antibodies 
alone.   For  a  person  who  has  anticardiolipin  antibodies,  the  higher  the 
antibody level, the greater the risk of developing a blood clot.8
MANAGEMENT OF ANTIPHOSPHOLIPID 
SYNDROME DURING PREGNANCY4
The ideal treatment for APLA during pregnancy should include:  
1. Improvement in maternal and fetal – neonatal outcome  by preventing 
Pregnancy loss, pre eclampsia, placental insufficiency and preterm birth
2. Reduction or elimination of the risk of thromboembolism.
At present, maternally administered heparin is considered as treatment 
of  choice.   It  is  usually  initiated  in  the  early  first  trimester  after 
ultrasonographic demonstration of a live embryo.  In most case series and 
trials, low dose aspirin is included in the treatment regimen.  
SUBCUTANEOUS HEPARIN REGIMENS USED FOR 
ANTIPHOSPHOLIPID SYNDROME DURING 
PREGNANCY4
1. PROPHYLACTIC REGIMENS
Recommended  in  women  with  no  history  of  thrombotic  events- 
diagnosis of recurrent preembryonic and embryonic loss or prior fetal death 
or  early  delivery  because  of  severe  preeclampsia  or  severe  placental 
insufficiency. 
STANDARD HEPARIN
7500-10000 U q12hourly in the first trimester, 10000U q 12hourly in 
the second and third trimester.
LOW MOLECULAR WEIGHT HEPARIN
1. Enoxaprin 40 mg once daily or dalteparin 5000U once daily.
2. Enoxaprin 30 mg q 12 h or dalteparin 5000 U q 12h
2. ANTICOAGULATION REGIMEN
Recommended in women with a history of thrombotic events.
STANDARD HEPARIN
        Every 8-12 hours, adjusted to maintain the midinterval heparin levels in 
the therapeutic range.
LOW MOLECULAR WEIGHT HEPARIN
1. Weight adjusted (enoxaparin 1mg/kg q  12 or dalteparin 200U/kg q 
12h )
2. Intermediate dose (enoxaparin 40 mg once daily or dalteparin 5000U 
once daily until 16 weeks of gestation and q 12h  from 16 weeks on).
Many centres are now using low molecular weight heparin, since it 
has  increased  bio  availability  and  a  longer  half  life  and  can  therefore 
conveniently be given once daily. It seems to have no greater deleterious 
effect on bone density than occurs physiologically during pregnancy.10
Women with APLA should be counselled about the potential risks of 
heparin therapy during pregnancy, including heparin induced osteoporosis 
and heparin induced thrombocytopenia(HIT). 
Osteoporosis  resulting in  fracture  occurs  in 1% to 2% of women 
treated  during  pregnancy.  Women  treated  with  heparin  should  be 
encouraged to take daily supplemental calcium and vitamin D (Eg. Prenatal 
vitamins).  It  also seems prudent to encourage daily axial  skeleton weight 
bearing exercise (Eg. Walking). LMWH is much less likely to be associated 
with  Heparin  induced  thrombocytopenia,  compared  with  unfractionated 
sodium heparin.
        IVIG has  also  been  used  in  pregnancy  complicated  by  APLA, 
especially  women  with  particularly  poor  past  histories  or  recurrent 
pregnancy loss during heparin treatment.4  Immunoglobulin is administered 
intravenously in doses of 0.4 g/kg daily for 5 days. This is repeated monthly 
or it is given as a single dose of 1g/kg each month. The drug may cause 
anaphylactic reactions, especially in women who have IgA deficiency due to 
anti IgA antibodies14. 
Hydroxychloroquine has been shown to diminish  the thrombogenic 
properties of APL antibodies in a murine thrombus model. 
Healthy women with recurrent embryonic and preembryonic loss and 
low titres of APLA don’t require treatment. The controlled trial of Pattison 
et al included majority of such women and found no difference in live birth 
rate in using low dose aspirin or placebo. 
PRE-PREGNANCY
Women with APLA should seek pre conception counselling. Patients 
should be informed about the risks of heparin induced osteoporosis.  And 
recommendations for appropriate protective measures should be provided. 
Primary APLA patients should be assessed for anaemia, thrombocytopenia 
and renal disease. 
PRENATAL    
            An early transvaginal ultrasound is useful to confirm an intrauterine 
pregnancy and for accurate dating. One of the anticoagulation prophylaxis 
should be started. Calcium supplementation should be encouraged. Prenatal 
visits should occur every 2 to 4 weeks until 20 to 24 weeks gestation and 
every  1  to  2  weeks  thereafter.  Because  of  the  risk  of  IUGR  and 
oligohydramnios, serial ultrasound examination should be performed every 
3 to 4 weeks after 17 to 18 weeks gestation. Antenatal surveillance should be 
initiated at 30 to 32 weeks.    
LABOUR AND DELIVERY
Patients  receiving prophylactic  anticoagulation with heparin can be 
instructed to withhold their injections at the onset of labour. Alternatively 
injections can be discontinued 12 hrs before a planned induction. In cases of 
extremely high risk for thromboembolism intravenous heparin can be started 
in  labour  and  discontinued  2  to  4  hrs  prior  to  anticipated  delivery. 
Intravenous heparin can be resumed 4 to 6 hrs after vaginal delivery and 12 
hrs after caesarean. 
POSTPARTUM
Warfarin thromboprophylaxis should be initiated as soon as delivery 
with doses adjusted to achieve an international normalised ratio of 3. Both 
heparin  and  warfarin  are  safe  for  breast  feeding  mothers.  Finally  oral 
contraceptives containing oestrogens are absolutely contraindicated
RESULTS OF TREATMENT
Although  improved  outcomes  are  reported  with  some  of  the 
treatments, Branch et al (2003) cautioned that recurrent fetal loss is still 20 
to 30%. In one study, Lockshin et al reported 23 of 32 women with prior 
fetal death and antiphospholipid antibody greater than 40Ig G units had a 
recurrent  fetal  death  despite  treatment  with  prednisone,  aspirin  or  both. 
Current  data  suggest  that  most  efficacious  therapy  to  be  low  dose 
heparin-7500 to 10,000 units administered subcutaneously, twice daily given 
along with low dose aspirin, 60 to 80 mg once daily. If active lupus also is 
present, then prednisone is usually also given usually.14   
        Retrospective case review of 82 consecutive pregnancies in women 
with  antiphospholipid  syndrome  with  varying  treatment  combination, 
including  prednisolone,  aspirin,  heparin  and  immunoglobulin  infusion. 
Outcomes were similar in all treatment groups, with 73% live birth, 60% 
Intra uterine growth retardation, 50%  preeclampsia or fetal distress,  37% 
delivering  preterm  and  5%  post  natal  thromboembolism.   Number  of 
previous pregnancy failures was the only significant  predictor  of  adverse 
pregnancy outcome (p=0.02). 50   
MATERIALS AND METHODS
MATERIALS AND METHODS
                 This study on anticardiolipin antibodies in unexplained pregnancy 
loss was carried out in 200 women with previous pregnancy loss in Govt. 
RSRM Hospital.  Study period was  2006-2008.  The  200 women were  of 
random gestational age.
The selection criteria were taken as follows:
i) Recurrent miscarriage ≥3
ii) Second  or  third  trimester  pregnancy  loss  which  includes  all 
intrauterine demises.
iii) Placental abruption
iv) H/O early onset preeclampsia
v) Intrauterine growth retardation 
vi) SLE 
vii) Thrombocytopenia
Exclusion criteria were as follows:
i) Anemia
ii) Diabetes mellitus
iii) Chronic Hypertension
iv) Renal Disorder
v) Sexually transmitted disorder
vi) Rh incompatibility
vii) Uterine anomalies
viii) Fetal anomalies
ix) Syphilis
About 5ml of serum was collected from the patients in a plain test tube.
Anticardiolipin  antibodies  encompass  IgG,  IgM  and  IgA  class  of 
antibodies, but in this study semi quantitative and qualitative determination 
of IgG antibodies in serum was done.
PRINCIPLE OF A PROCEDURE
An  indirect  Non-competitive  enzyme  immunoassay  for  the  semi 
quantitative and qualitative determination of cardiolipin IgG antibodies is 
performed.  The  wells  of  the  microtitre  plate  are  coated  with  cardiolipin 
antigen. Antibodies specific for cardiolipin present in the patient’s sample 
bind to the antigen.
The second step, the antigen antibody complex reacts with an enzyme 
labelled second antibody (Enzyme Conjugate) which leads to the formation 
of  an  enzyme  labelled  antigen  antibody  sandwich  complex.  The  enzyme 
label converts added substrate from a colored solution. 
The  rate  of  colour  formation  from the  chromogen is  a  function  of 
enzyme  conjugate  complexed  with  the  bound  antibody  and  this  is 
proportional to the initial concentration of the respective antibodies in the 
patient’s sample.
Materials Required
Standards 6 vials of cardiolipin antibody 
standards at concentrations of 
0-4-8-20-50-100 GPL- u/ml
Positive Control 1 vial
Negative Control 1 vial
Wash buffer
Sample buffer
Conjugate 1 vial of antihuman IgG horse 
radish per-oxidase conjugate
Enzyme Substrate 1 vial of Tetra methyl benzene
Microtitre well strips
Microtitre plate reader
Distilled H2O
Glass ware
Micro pipettes (10, 50, 100, 1000µl) 
or multi pipette.
Procedure
1. Wash wells one time with wash buffer immediately prior to use.
2. Dilute Serum/plasma (1:101)
3. Dispense 100µl of standards, controls and diluted patient samples in 
to appropriate wells.
4. Incubate for 30 minutes
5. Aspirate fluid from wells and wash wells 3-5 times with wash buffer.
6. Dispense 100µl of conjugates in to all wells.
7. Incubate for 30 minutes.
8. Aspirate fluid from wells and wash wells 3-5 times with wash buffer
9. Dispense 100µl of Enzyme substrate in to all wells.
10.Incubate for 10 minutes in the dark.
11. Dispense 50µl of stop solution in to all wells.
12.Read absorbance (OD) at 450 nm within 30 minutes of adding the 
stop solution
INTERPRETATION OF RESULTS
Photometric quantitation is made at 450 nm using a microtitre plate 
photometer. A standard curve is obtained from the linear plot of normalized 
optical densities (OD Mean/O.D max 1) (i.e.) OD of the individual standard 
samples divided by the O.D. of the highest standard. The concentrations of 
the  control  and  patient  samples  are  then  determined  by  comparing  the 
normalized  optical  densities  for  each  unknown to  the  standard  airne  and 
reading of the corresponding concentrations.
For the assessment of patient’s sera the following range is recommended.
Negative       :         <12 GPL u/ml
Equivocal     :          12-18 GPL u/ml
Positive        :           >18 GPL u/ml
                                       
OBSERVATION
OBSERVATION
          This study regarding Anti-Cardiolipin antibodies in unexplained 
pregnancy  loss  was  carried  out  on  200  pregnant  women  with  previous 
pregnancy wastage. They were selected after ruling out the other possible 
causes  such as  Diabetes,  syphilis,  etc.  Detection of  these  anti-cardiolipin 
antibodies  was  done  by  measuring  the  IgG antibodies  by  Elisa  method. 
Values of more than 18 GPL u/ml were taken as positive.
TABLE 1
AGE DISTRIBUTION OF SUBJECTS
Age in Years No. of Patients Percentage
18-20 30 15%
21-25 92 46%
26-30 52 26%
31-35 26 13%
Table I shows age distribution of 200 patients with unexplained pregnancy 
loss.
Maximum number of patients belong to the age group 21-25 [46%] 
followed by the age group 26-30[26%]. 15% belong to age group 18-20 and 
13% along to age group 31-35.
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TABLE II
CONCEPTION DISTRIBUTION OF SUBJECTS
Gravida No. of Subjects Percentage
PRIMI Gravida                     8 4%
II 78 39%
III 62 31%
IV 36 18%
V 12 6%
VI & above 4 2%
Table II shows the distribution of conceptions among the test subjects. 
Maximum no. of cases were under the group of Gravida II [39%]. This was 
followed by Gravida III group which was about 31%. 18% were IV gravida, 
6% were V gravidas 4% were primis and 2% VI gravida and above.
CONCEPTION DISTRIBUTION OF SUBJECTS
0%
5%
10%
15%
20%
25%
30%
35%
40%
PERCENTAGE
PRIMI
Gravida
II III IV V VI &
above
PRIMI GRAVIDA
TABLE III
GESTATIONAL AGE DISTRIBUTION OF SUBJECTS
Gestational Age No.of Subjects Percentage
I Trimester 20 10%
II Trimester 22 11%
III Trimester 158 79%
Table  III  shows  dramatic  accumulation  under  III  trimester  which 
tallies around 79%. 11% of cases were in the II trimester and 10% of cases 
in the I trimester.
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TABLE IV
                   OBSTETRIC HISTORY OF SUBJECTS
Type of Loss No. of Cases Percentage
Abortion ≥ 3 48 24%
Intrauterine demise 84 42%
Intrauterine growth retardation 34 17%
Abruption 24 12%
Early onset PIH 10 5%
Table IV shows the  obstetric history of subjects taken for the study. 
Maximum  numbers  of  cases  included  were  intrauterine  demise  42% 
followed  by  abortion  ≥  3  24%,  intrauterine  growth  retardation  17%, 
abruption 12%, early onset PIH 5%.
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NOW CONSIDERING THE POSITIVE CASES WHICH TURNED OUT 
TO BE EIGHTEEN OF TWO HUNDRED.
TABLE V
CONCEPTION DISTRIBUTION OF POSITIVE CASES
Gravida No. of Subjects Percentage
PRIMI Gravida - -
Gr  II 10 56%
Gr  III - -
Gr IV 6 33%
Gr  V - -
Gr VI 2 11%
          55.5% of the positive cases happened to be 2nd gravida followed by 4th 
gravida who occupied  33%. 11.1% were gravida VI and none in the primi 
or gravida V
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TABLE VI
GESTATIONAL AGE DISTRIBUTION IN POSITIVE CASES
Gestational Age No.of Subjects Percentage
I Trimester 2 11%
II Trimester 6 33%
III Trimester 10 56%
The  above  important  table  shows  that  maximum  number  of  cases 
presented  to  us  at  the  third  trimester  [55.5%]  followed  by  33.3%  in  II 
trimester and 11.1% in I trimester.
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      TABLE VII
        OBSTETRIC HISTORY IN POSITIVE CASES
Type of Loss No. of Cases Percentage
Abortion ≥ 3 2 11%
Intrauterine demise 8 45%
Intrauterine growth retardation 2 11%
Abruption 2 11%
Early onset PIH 2 11%
Mixed Presentation 2 11%
This  table  VII  gives  an  insight  in  to  the   obstetric  history  in  the 
positive cases. The majority were intrauterine deaths (44.4%) and abortions. 
Intrauterine  growth retardation  babies,  Abruptio  placenta  and early  onset 
preeclampsia all taking on equal share of 11.1%. Mixed presentation (i.e.) 
abruption and preelcampsia or abruption and live births etc. also occupied 
11.1%
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TABLE VIII
PRESENT OBSTETRIC OUTCOME IN POSITIVE CASES
Type of Loss No. of Cases Percentage
Abortion - -
Intrauterine demise 10 55.5%
Live Births 4 22.2%
         1. Intrauterine growth retardation 2 11.1%
         2. SGA/PT 2 11.1%
Abruption 2 11.1%
Early onset PIH 2 11.1%
Live  Birth  was  seen  in  22.2%  of  cases,  but  included  Small  for 
gestational babies (SGA) babies/Intrauterine growth retardation babies and 
had an episode of abruption too. Intrauterine demises were seen in 55.5% of 
cases. 11.1% were  intrauterine growth retarded, recurrent preeclampsia and 
Abruption. None of the cases ended up with abortions.
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DISCUSSION
   
DISCUSSION
This study was undertaken to analyse the following facts;
a) The prevalence of Anti-Cardiolipin antibodies in patients with            
     unexplained pregnancy loss.
b) The importance of screening patients with bad obstetric history for    
     anticardiolipin antibodies.
c) Criteria for selection for screening of these patients
d) The kind of obstetric outcome that is more common in anticardiolipin   
     antibody positive women.
e) Follow up the rest of the pregnancy to see the pregnancy outcome.
Two Hundred patients with unexplained pregnancy loss in the past 
were taken up for study in the Govt. RSRM lying-in hospital, attached to 
Stanley  Medical  College.  These  women  were  thoroughly  screened  for 
Diabetes,  syphilis,  urinary  tract  infections,  Torch  infections  before 
subjecting them for anti cardiolipin anti body screening.
The criteria for screening women for anticardiolipin antibodies were,
i) Recurrent miscarriage ≥3
ii) Second or third trimester pregnancy loss which includes all IUD’s
iii) Placental abruption
iv) H/O Early onset preeclampsia
v) Intrauterine growth retardation
vi) SLE
vii) Thrombocytopenia
None of the patients we selected had either SLE or thrombocytopenia.
The mean age of the patient in this study was 25. Maximum number 
of patients belonged to the age group [21-25]. The youngest patient in our 
study was 18yrs old and eldest 35yrs.
In DERKSON et al.’s study of anti cardiolipin antibodies in recurrent 
pregnancy loss, the mean age was 31 yrs. In Friedman’s study mean age was 
32  yrs.  The  increase  in  incidence  in  younger  patients  in  this  study  is 
probably due to the early marriage in our society.
39% of patients in this study were II gravidae followed closely by III 
gravidae  [31%].  The  increase  in  2nd gravidae  in  our  study  is  probably 
because of the criteria taken for selection. Even 2nd (OR) 3rd trimester loss 
was taken as a criterion for screening and this resulted in increase in number 
of 2nd gravidae.
Almost 79% of patients screened were in their 3rd trimesters, which 
probably is due to our patients presenting more in term either with false or 
true labour pains. (i.e.) most of them were unbooked cases.
Among the 200 women screened, 18 turned out to be positive for IgG 
class of anticardiolipin antibodies. This 9% is quite a number compared to 
other studies.
RAI et al. studied women with recurrent miscarriages and showed a 
prevalence of 5.5% of anticardiolipin antibody positive in them.32 LYNCH et 
al. in his study showed a prevalence of 15.8% of anticardiolipin antibodies 
in  women with intrauterine fetal  deaths.  36  EROGLU et  al.  in  this  study 
suggested that the prevalence of anticardiolipin antibody is very low in first 
trimester  losses  and  is  not  very  significant. 33 But  MACLEAN  and 
colleagues in their study proved that there was a prevalence of 8.2% in first 
trimester losses. 34
But most of these studies have shown the prevalence of anticardiolipin 
antibodies  in  individual  adverse  outcomes  either  in  miscarriages  or  in 
intrauterine deaths etc. But our study shows the prevalence of anticardiolipin 
antibodies  in  a  high  risk  population  which  includes  recurrent  abortions, 
intrauterine deaths, intrauterine growth retardation etc.
According  to  KALRA  et  al.,  anticardiolipin  antibody  IgM  is  not 
associated with first trimester recurrent abortion. 15 But as per LOCKWOOD 
et al., (1986) in his study of 55 patients showed that 18% of women with 
poor obstetric outcome had raised level of anticardiolipin antibody IgM. 39
Eve Scopelitis et al., did a study in African American population and 
concluded that positivity for anticardiolipin antibodies is associated with an 
increased risk for fetal loss and not for other complications for pregnancy. 16 
Velayutha Prabhu et al in his study of in their study of 155 patients with 
recurrent spontaneous abortions concluded that the levels of anticardiolipin 
antibody IgG were detected as 40%17.
Anne  Lynch  et  al  did  a  study  to  determine  if  the  presence  of 
antiphospholipid  antibody  in  healthy  pregnant  women  in  associated  with 
adverse pregnancy outcome including 
1. Intra uterine fetal loss
2. Maternal pregnancy complications
3. Low birth weight
4. Low 5 min apgar score 
 The study concluded that patients with elevated APL levels at their 
initial prenatal visit had an increased  fetal loss but no increase in maternal, 
pregnancy  complications,  low  birth  weight  or  low  apgar  score. 
Immunoglobulin G anticardiolipin antibody was the only single test of APL 
significantly associated with fetal loss. 18 
Mary Bird Sall et al., in her study assessed the relationship between 
antiphospholipid  antibodies  and  recurrent  miscarriage,  fetal  death,  and 
pregnancy complications-placental  abruption,  fetal  growth retardation and 
preeclampsia.  The  subjects  were 81 women with a  history of  3  or  more 
miscarriages, 62 with a history of fetal death in the index pregnancy, 105 
with  a  poor  obstetric  history  or  pregnancy  complications  and  13  with 
systemic lupus erythematosus. 
Antiphospholipid  antibodies  were  found  in  41%  of  women  with 
history of recurrent miscarriage, 29% with the history of recent fetal death, 
19% with a poor obstetric history and she concluded that patients with the 
above pregnancy disorders should be tested for antiphospholipid antibodies 
because of the risk conferred on their fetus by their presence and to expand 
the treatment options. 22
Kaneria et al., did a pilot study in 50 patients of bad obstetric history 
for the presence of lupus anticoagulant and anticardiolipin antibodies. LA 
alone was positive in 6 patients (12%) and ACLA alone was positive in 14 
patients (28%) while both LA and ACLA were positive in 3 patients (6%)20
Kumar et al., did a study with 150 patients with recurrent pregnancy 
loss in South India and found 11 patients positive for ACLA and suggested 
the usefulness of screening for these antibodies as a mandatory routine for 
instituting  efficient  therapeutic  regimes  for  a  successful  outcome  of 
pregnancy. 2
The  commonest  type  of  obstetric  history  in  our  antiphospholipid 
antibody  positive  women  is  intrauterine  death  which  occupies  a  55.5% 
followed  by   Intrauterine  growth  retardation,  abruption  and  early  onset 
preeclampsia all of which are around 11.1%.
This probably tallies well with BOCCIOLONE et al’s observation that 
intrauterine late foetal death is more common in anti cardiolipin antibody 
positive  than  in  lupus  anti  coagulant  positive.  Recurrent  spontaneous 
abortions  according  to  him  were  more  common  in  lupus  anticoagulant 
positive than anticardiolipin antibodies positive. In this observation 11% of 
anticardiolipin antibody positive had intrauterine demises.
DERIK’S et at., in his retrospective analysis found out that 80% of 
women with anticardiolipin antibodies had at least one fetal death compared 
with less than 25% of women without. The specificity according to him for 
the  presence  of  anti  phospholipid  antibodies  in  patients  with  recurrent 
pregnancy loss was 76%. In contrast, 2 or earlier first trimester losses had a 
specificity  of  only  6%.  Thus  they  concluded  that  foetal  death  is  more 
characteristic  of  the  type  of  loss  experienced  by  patients  with  recurrent 
pregnancy  loss  than  early  first  trimester  pregnancy  loss  in  patient  with 
Anticardiolipin antibody37. Live birth rate in this study was around 22.2% 
(i.e.  4 out of 18 patients) where 2 were SGA and preterm and 1 was an 
intrauterine growth retarded baby.
                             
SUMMARY
SUMMARY
Two Hundred pregnant women with previous unexplained pregnancy 
loss were taken for this study, to detect for the presence of anticardiolipin 
antibodies, with the idea that these antibodies might be the one responsible 
for their pregnancy loss. This suggestion is made after screening them for all 
other possible causes.
1). In the study group eighteen of them tested positive for anticardiolipin 
antibodies. In this positive group, more than half of them (55.5%) were 2nd 
gravidae.
2). The Mean age of the patient in this study was 25.
3). Maximum number of patients belongs to the age group of 21-25 years. 
4). The youngest patient in our study was 18 years old and eldest 35 years.
5). 39% of patients in this study were second Gravida
6). A majority of them [55.5%] presented to us only in the third trimester 
either with c/o loss of foetal movements, bleeding p/v or just with onset of 
labour contractions. 
7). An analysis of the previous obstetric history revealed that intrauterine 
deaths were the predominant presentation [45%] followed next only by other 
presentations like abortions, abruptions etc.
8). A follow up of the present pregnancy also showed that IUD’s were in the 
forefront (55.5%)
9). Live birth rate was 22.2% which  included 11.1% intrauterine growth 
retardation, 11.1% small for gestational age / preterm.
10). 11.1% had abruption, 11.1% had early onset PIH.
            
CONCLUSION
CONCLUSION
In this study, women  who  are  positive for  anticardiolipin  antibody 
have  a  significant  risk  of  reproductive  failure  and  adverse  pregnancy 
outcome. The incidence of recurrent abortion, foetal death and intrauterine 
growth retardation is significant.
THIS STUDY PROVES THAT ANTICARDIOLIPIN ANTIBODIES 
ARE ASSOCIATED WITH SIGNIFICANT FOETAL LOSS. SECOND 
AND THIRD TRIMESTER LOSSES IN THE FORM OF INTRAUTERINE 
DEATHS WERE THE COMMONEST OBSTETRIC OUTCOME.
            Women with unexplained loss should essentially be screened for 
anticardiolipin antibodies and this should be a part of investigation protocol 
followed. As a best management practice, screening should be done earlier, 
as soon as the pregnancy test becomes positive.
              The best approach, to be professed is to form  multidisciplinary 
teams for management methods to exclude other causes of pregnancy loss, 
lay down the proper criterion for screening for ACL, and select the perfect 
regimen which will cause the least harm to both the mother and the fetus.
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PROFORMA
NAME: AGE: IPNO: UNIT:
ADDRESS: OCCUPTION:
INCOME: SOCIOECONOMIC STATUS:
DOA:
PARITY INDEX:
LMP    EDD PERIOD OF GESTN
PRESENTING COMPLAINTS:
MENSTURAL HISTORY:
MARITAL HISTORY:
OBSTETRIC HISTROY:
PREVIOUS OBSTETRIC HISTORY:
ABORTION::
NUMBER
GESTATIONAL AGE
CONGENITAL ANOMALY
TYPE
STILL BORN::
NUMBER
GESTATIONAL AGE
FRESH OR MACERATED
SEX
WEIGHT
CONGENITAL ANOMALY
NEONATAL DEATH::
NUMBER
CAUSE
PRETERM BIRTH::
NUMBER
GESTATIONAL AGE
H/O PROM
OUTCOME
LIVE BIRTH::
NUMBER
WEIGHT
SEX
CONGENITAL ANOMALY
PRESENT HEALTH
HISTORY OF ANY PREDISPOSING FACTOR TO BOH
HISTORY OF PRESENT PREGNANCY
PAST HISTORY
PERSONAL HISTORY
FAMILY HISTORY
GENERAL EXAMINATION
HEIGHT WEIGHT
PALLOR ODEMA
PULSE BP
BREAST THYROID
CVS CNS
OBSTERTIC EXAMINATION
INVESTIGATION:
URINE ROUTINE EXAMINATION
COMPLETE HEMOGRAM
BLOOD GROUPING & Rh TYPING:
VDRL:
BLOOD SUGAR/GTT::
BLOOD UREA:: S.CREATININE::
SERUM URIC ACID:: S.BILIRUBIN::
BT :: CT::
ULTRASOUND
ELISA FOR IgG ACA
PREGNANCY OUTCOME
MASTERCHART
Sl.No Name Age Ipno Unit Parity GA/Week ACLA Pregnancy Outcome
1 Sirajunisha 23 34449 II G4P2L0A1 8w Positive SGA
         
2 Kondammal 28 10215 I G5P4L1 12w Negative Abortion
         
3 Devi 26 29975 II G2P1L0 24w Negative Live Baby
         
4 Geetha 22 18827 IV G3P1L0A1 36w Negative IUGR
         
5 Bhuvaneswari 23 17190 IV G2P1L0 34w Negative IUGR
         
6 Aruna 20 7646 III G2P1L0 34w Negative IUD
         
7 Ammu 23 26430 I G3P2L0 28w Negative Live Baby
         
8 Karishma 28 22656 IV G3P2L0 32w Negative PIH
         
9 Kanjana 25 34261 IV G2P1L0 36w Negative Live Baby
         
10 Shakila Devi 19 26025 I G3P2L0 18w Negative Live Baby
         
11 Madhavi 23 26200 II G2P1L0 22w Positive Abruption
         
12 Gomathi 22 22894 IV G3P1L0A1 34w Negative Live Baby
         
13 Sulochana 20 300591 I G6P3L1A2 32w Negative IUGR
         
14 Shakila 29 28376 II G5A4 34w Negative Live Baby
         
15 Multhani 22 36074 IV G2P1L0 32w Negative Live Baby
         
16 Yamuna 29 36050 IV G2P1L0 36w Negative Live Baby
         
17 Saraswathy 26 984 V G2P1L0 34w Negative Live Baby
         
18 Tamilselvi 23 14445 III G5P2L1A2 30w Negative IUGR
         
19 Yasodha 30 37021 I G2P1L0 20w Positive IUD
         
20 Renuka 22 38723 II G3P1L0A1 28w Negative SGA
         
21 Parvathy 32 19559 IV G2P1L0 29w Negative Live Baby
22 Selvi 24 17321 IV G2P1L0 11w Negative Live Baby
         
23 Saroja 23 19645 IV G4P1L1A2 33w Negative Live Baby
         
24 Eswari 22 7143 V G2P1L0 32w Negative Live Baby
         
25 Varalakshmi 32 17390 I G4P2L1A1 30w Negative Live Baby
         
26 Sumathi 33 20897 II G4A3 34w Negative Early PIH
         
27 Padmavathi 25 18675 IV PRIMI 22w Negative Live Baby
         
28 Savithri 18 16421 I G2P1L0 34w Negative Abruption
         
29 Kupamma 20 7644 II G2P1L0 32w Negative Live Baby
         
30 Ammu 22 8612 III G4P2L1A1 30w Negative Live Baby
         
31 Aruna 24 11242 I G2P1L0 36w Negative Live baby
         
32 Jency 26 11264 IV G2P1L0 28w Positive IUD
         
33
Wahidh 
Begum 28 16241 V G3P1L0A1 30w Negative Live Baby
         
34 Kanniyamal 29 18926 II G2P1L0 31w Negative Live Baby
         
35 Mari 28 19321 III G3P1L0A1 32w Negative Live Baby
         
36 Muthamal 30 6499 IV G2P1L0 32w Negative IUGR
         
37 Jeyanthi 31 73641 I G4P2L0A1 11w Negative Live Baby
         
38 Mani 20 11211 II G3P2L0 35w Negative Live Baby
         
39 Banu 22 20629 I PRIMI 34w Negative Live Baby
         
40 Raayamma 20 20612 I G2P1L0 33w Negative Live Baby
         
41 Kavitha 26 15941 IV G2P1L0 32w Negative Live Baby
         
42 Rekha 24 16921 III G3P2L0 33w Negative SGA
         
43 Priya 18 10432 II G3P1L0A1 31w Negative Live Baby
         
44 Sivagami 19 20672 III G2P1L1 30w Positive IUD
         
45 Usha 21 11324 III G2P1L0 11w Negative Live Baby
46 Devi 23 11431 I G2P1L0 35w Negative Live Baby
         
47 Shankari 24 16789 I G2P1L0 29w Negative Live Baby
         
48 Krishna 32 9994 I G3P2L0 30w Negative Live Baby
         
49 Yuvarani 22 9443 III G2P1L0 31w Negative Live Baby
         
50 Sandhya 23 17621 III PRIMI 32w Negative Live Baby
         
51 Ramya 26 42611 I G3P2L1 34w Negative IUGR
         
52 Rahini 27 9734 II G3P2L0 32w Negative SGA
         
53 Katammal 28 162112 V G2P1L0 30w Negative Live Baby
         
54 Laskhmi 22 10621 IV G2P1L0 32w Positive IUGR
         
55 Seetha 26 13622 III G3P1L0A1 30w Negative Live Baby
         
56 Bavani 24 11341 I G2P1L0 34w Negative IUGR
         
57 Dhanalaskhmi 25 1246 I G2P1L0 29w Negative IUD
         
58 Bhuvana 18 10642 III PRIMI 30w Negative SGA
         
59 Chitra 19 96212 I G4P1L1A2 11w Negative Live Baby
         
60 SivaSankari 21 94211 II G2P1L0 32w Negative Live Baby
         
61 Kumari 29 9334 III G2P1L0 33w Negative Abruption
         
62 Aaandal 31 10421 III G2P1L0 7w Negative Live Baby
         
63 Priyadarshini 30 16231 I G3P2L0 34w Negative Live Baby
         
64 Shakunthala 24 1033 I G4P3L1 34w Positive Early Onset PIH
         
65 Amala 30 6080 III G3P1L0A1 32w Negative Abortion
         
66 Meenatchi 23 18779 II G4A3 34w Negative Live Baby
         
67 Rathi 27 15995 II G4P1L0A2 30w Positive IUD
         
68 Saraswati 21 12800 I G5P2L1A2 28w Negative Live Baby
         
69 Ameena 24 17658 I G5P2L1A2 32w Negative SGA
70 Komala 22 6460 III G3P2L0 32w Negative IUGR
         
71 Zareena 25 20577 IV G3P2L0 30w Negative Live Baby
         
72 Shajidha 23 20558 IV G3P1L0A1 30w Negative Live Baby
         
73 Poongodi 23 6479 III G3P2L0 30w Negative Live Baby
         
74 Jayanthi 29 12645 I G3P1L0A1 32w Negative IUGR
         
75 Datchayini 30 24890 III G4P1L1A2 32w Negative Live Baby
         
76 Maleshwari 22 15014 IV G4P2L1A1 34w Negative IUGR
         
77 Manju 20 33385 I G3P2L0 30w Negative Live Baby
         
78 Komala 31 19041 II G3P1L0A1 32w Negative Live Baby
         
79 Ameena 24 17658 IV G5P2L1A2 34w Negative IUD
         
80 Latha 26 6513 I G4P2L1A1 34w Negative Live Baby
         
81 Amaravathi 20 18063 III G6A5 30w Positive IUD
         
82 Anandhi 23 7810 I G4P2L0A1 34w Negative Live Baby
         
83 Masthani 22 10090 IV G4P1L1A2 32w Negative Live Baby
         
84 Usha 20 9946 I G4A3 30w Negative SGA
         
85 Manjula 35 9993 II G3P1L0A1 34w Negative Live Baby
         
86 Lashmikantha 26 12746 I G2P1L0 8w Negative Live Baby
         
87 Saranya 28 14721 IV G4P1L0A2 32w Negative Live Baby
         
88 Sajitha Banu 27 14521 I G2P1L0 28w Negative Live Baby
         
89 Chandrakala 25 12726 IV G2P1L0 34w Negative Preterm
         
90 Angammal 24 83851 V G3P1L0A1 34w Negative IUGR
         
91 Beulah 25 10080 III G3P1L0A1 38w Negative Live Baby
         
92 Murugammal 23 45141 II G2P1L0 36w Negative Live Baby
         
93 Shyamala 24 18841 III G3P2L0 34w Negative Live Baby
94 Kalavathy 25 26212 IV G3P1L0A1 34w Negative Live Baby
         
95 Nirmala 24 34242 II G3P1L0A1 32w Negative IUD
         
96 Rajeswari 23 42612 III G2P1L0 28w Negative Live Baby
         
97 Rekha 24 14321 I G2P1L0 32w Negative Abortion
         
98 Amudha 25 33862 I G3P1L0A1 34w Negative SGA
        
99 Vatchala 24 15262 III G4A3 32w Negative Live Baby
         
100 Bharathi 23 16241 IV G2P1L0 12w Negative Live Baby
101 Ambiga 23 14449 II G4P2L0A1 8w Positive SGA
         
102 Pushpanjali 28 16777 I G5P4L1 12w Negative Abortion
         
103 Manju 26 19876 II G2P1L0 24w Negative Live Baby
         
104 Nasiya 22 13327 IV G3P1L0A1 36w Negative IUGR
         
105 Rajalakshmi 23 17233 IV G2P1L0 34w Negative IUGR
         
106 Gracy Shoba 20 17646 III G2P1L0 34w Negative IUD
         
107 Sumithra 23 26430 I G3P2L0 28w Negative Live Baby
         
108 Gunavathy 28 22656 IV G3P2L0 32w Negative PIH
         
109 Selvi 25 34261 IV G2P1L0 36w Negative Live Baby
         
110 Rajeswari 19 26025 I G3P2L0 18w Negative Live Baby
         
111 Farziya Banu 23 26200 II G2P1L0 22w Positive Abruption
         
112 Amulu 22 22894 IV G3P1L0A1 34w Negative Live Baby
         
113 Lalitha 20 300591 I G6P3L1A2 32w Negative IUGR
         
114 Kasthuri 29 28376 II G5A4 34w Negative Live Baby
         
115 Ellammal 22 36074 IV G2P1L0 32w Negative Live Baby
         
116 Rani 29 36050 IV G2P1L0 36w Negative Live Baby
         
117 Sulochana 26 984 V G2P1L0 34w Negative Live Baby
118 Sarala 23 14445 III G5P2L1A2 30w Negative IUGR
         
119 Nagamuthu 30 37021 I G2P1L0 20w Positive IUD
         
120 Usha 22 38723 II G3P1L0A1 28w Negative SGA
         
121 Kumari 32 19559 IV G2P1L0 29w Negative Live Baby
         
122 Kamala 24 17321 IV G2P1L0 11w Negative Live Baby
         
123 Valarmathi 23 19645 IV G4P1L1A2 33w Negative Live Baby
         
124 Kalyani 22 7143 V G2P1L0 32w Negative Live Baby
         
125 Sabitha 32 17390 I G4P2L1A1 30w Negative Live Baby
         
126 Anjali devi 33 20897 II G4A3 34w Negative Early PIH
         
127 Sudha 25 18675 IV PRIMI 22w Negative Live Baby
         
128 Srideepa 18 16421 I G2P1L0 34w Negative Abruption
         
129 Parameswari 20 7644 II G2P1L0 32w Negative Live Baby
         
130 Muniammal 22 8612 III G4P2L1A1 30w Negative Live Baby
         
131 Kumudha 24 11242 I G2P1L0 36w Negative Live baby
         
132 Indiramathy 26 11264 IV G2P1L0 28w Positive IUD
         
133 Thareswari 28 16241 V G3P1L0A1 30w Negative Live Baby
         
134 Vijaya 29 18926 II G2P1L0 31w Negative Live Baby
         
135 Radhika 28 19321 III G3P1L0A1 32w Negative Live Baby
         
136 Gauthami 30 6499 IV G2P1L0 32w Negative IUGR
         
137 Sargu 31 73641 I G4P2L0A1 11w Negative Live Baby
         
138 Anaswathy 20 11211 II G3P2L0 35w Negative Live Baby
         
139 Padma 22 20629 I PRIMI 34w Negative Live Baby
         
140 Eswari 20 20612 I G2P1L0 33w Negative Live Baby
         
141 Tamilarasi 26 15941 IV G2P1L0 32w Negative Live Baby
142 Soundari 24 16921 III G3P2L0 33w Negative SGA
         
143 Vaali 18 10432 II G3P1L0A1 31w Negative Live Baby
         
144 Jayanthi 19 20672 III G2P1L1 30w Positive IUD
         
145 Saradha 21 11324 III G2P1L0 11w Negative Live Baby
         
146 Yasodha 23 11431 I G2P1L0 35w Negative Live Baby
         
147 Jayammal 24 16789 I G2P1L0 29w Negative Live Baby
         
148 Gowri 32 9994 I G3P2L0 30w Negative Live Baby
         
149 Saraswathi 22 9443 III G2P1L0 31w Negative Live Baby
         
150 Latha 23 17621 III PRIMI 32w Negative Live Baby
         
151 Poongodi 26 42611 I G3P2L1 34w Negative IUGR
         
152 Chandra 27 9734 II G3P2L0 32w Negative SGA
         
153 Saroja 28 162112 V G2P1L0 30w Negative Live Baby
         
154 Tamilselvi 22 15461 IV G2P1L0 32w Positive IUGR
         
155 Seetha 26 13622 III G3P1L0A1 30w Negative Live Baby
         
156 Sathya 24 11341 I G2P1L0 34w Negative IUGR
         
157 Gayathri 25 1246 I G2P1L0 29w Negative IUD
         
158 Muthamma 18 10642 III PRIMI 30w Negative SGA
         
159 Manjula 19 96212 I G4P1L1A2 11w Negative Live Baby
         
160 Sathiya 21 94211 II G2P1L0 32w Negative Live Baby
         
161 Kumari 29 9334 III G2P1L0 33w Negative Abruption
         
162 Vijaya 31 10421 III G2P1L0 7w Negative Live Baby
         
163 Priyadarshini 30 16231 I G3P2L0 34w Negative Live Baby
         
164 Sheeba 24 12673 I G4P3L1 34w Positive Early Onset PIH
         
165 Nithya 30 6080 III G3P1L0A1 32w Negative Abortion
166 Ramadevi 23 18779 II G4A3 34w Negative Live Baby
         
167 Sahana 27 15454 II G4P1L0A2 30w Positive IUD
         
168 Sree 21 12800 I G5P2L1A2 28w Negative Live Baby
         
169 Rani 24 17658 I G5P2L1A2 32w Negative SGA
         
170 Komala 22 6460 III G3P2L0 32w Negative IUGR
         
171 Zareena 25 20577 IV G3P2L0 30w Negative Live Baby
         
172 Shajidha 23 20558 IV G3P1L0A1 30w Negative Live Baby
         
173 Poongodi 23 6479 III G3P2L0 30w Negative Live Baby
         
174 Jayanthi 29 12645 I G3P1L0A1 32w Negative IUGR
         
175 Datchayini 30 24890 III G4P1L1A2 32w Negative Live Baby
         
176 Maleshwari 22 15014 IV G4P2L1A1 34w Negative IUGR
         
177 Manju 20 33385 I G3P2L0 30w Negative Live Baby
         
178 Komala 31 19041 II G3P1L0A1 32w Negative Live Baby
         
179 Ameena 24 17658 IV G5P2L1A2 34w Negative IUD
         
180 Latha 26 6513 I G4P2L1A1 34w Negative Live Baby
         
181 Sarasu 20 19600 III G6A5 30w Positive IUD
         
182 Anandhi 23 7810 I G4P2L0A1 34w Negative Live Baby
         
183 Masthani 22 10090 IV G4P1L1A2 32w Negative Live Baby
         
184 Usha 20 9946 I G4A3 30w Negative SGA
         
185 Manjula 35 9993 II G3P1L0A1 34w Negative Live Baby
         
186 Lashmikantha 26 12746 I G2P1L0 8w Negative Live Baby
         
187 Saranya 28 14721 IV G4P1L0A2 32w Negative Live Baby
         
188 Sajitha Banu 27 14521 I G2P1L0 28w Negative Live Baby
         
189 Chandrakala 25 12726 IV G2P1L0 34w Negative Preterm
190 Kumudha 24 83851 V G3P1L0A1 34w Negative IUGR
         
191 Rajeswari 25 10080 III G3P1L0A1 38w Negative Live Baby
         
192 Durgadevi 23 45141 II G2P1L0 36w Negative Live Baby
         
193 Sangeetha 24 18841 III G3P2L0 34w Negative Live Baby
         
194 Jeevitha 25 26212 IV G3P1L0A1 34w Negative Live Baby
         
195 Vasanthi 24 34242 II G3P1L0A1 32w Negative IUD
         
196 Anandhi 23 42612 III G2P1L0 28w Negative Live Baby
         
197 Sujatha 24 14321 I G2P1L0 32w Negative Abortion
         
198 Priya 25 33862 I G3P1L0A1 34w Negative SGA
        
199 Bhoopathy 24 15262 III G4A3 32w Negative Live Baby
         
200 Kushboo 23 16241 IV G2P1L0 12w Negative Live Baby
